Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 3
1998 1
2001 1
2002 3
2003 5
2004 3
2005 4
2006 4
2007 2
2008 7
2009 5
2010 11
2011 18
2012 25
2013 28
2014 18
2015 23
2016 24
2017 30
2018 25
2019 27
2020 51
2021 55
2022 42
2023 29

Text availability

Article attribute

Article type

Publication date

Search Results

376 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Daley CL, et al. Among authors: winthrop kl. Eur Respir J. 2020 Jul 7;56(1):2000535. doi: 10.1183/13993003.00535-2020. Print 2020 Jul. Eur Respir J. 2020. PMID: 32636299 Free PMC article.
COVID-19 vaccination and antirheumatic therapy.
Arnold J, Winthrop K, Emery P. Arnold J, et al. Among authors: winthrop k. Rheumatology (Oxford). 2021 Aug 2;60(8):3496-3502. doi: 10.1093/rheumatology/keab223. Rheumatology (Oxford). 2021. PMID: 33710296 Free PMC article. Review.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, de Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland TPM, Westhovens R, van der Heijde D. Smolen JS, et al. Among authors: winthrop kl. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10. Ann Rheum Dis. 2023. PMID: 36357155
Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases.
Lange C, Böttger EC, Cambau E, Griffith DE, Guglielmetti L, van Ingen J, Knight SL, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, Wagner D, Winthrop K, Daley CL; expert panel group for management recommendations in non-tuberculous mycobacterial pulmonary diseases. Lange C, et al. Among authors: winthrop k. Lancet Infect Dis. 2022 Jul;22(7):e178-e190. doi: 10.1016/S1473-3099(21)00586-7. Epub 2022 Jan 25. Lancet Infect Dis. 2022. PMID: 35090639 Review.
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS. Nash P, et al. Among authors: winthrop kl. Ann Rheum Dis. 2021 Jan;80(1):71-87. doi: 10.1136/annrheumdis-2020-218398. Epub 2020 Nov 6. Ann Rheum Dis. 2021. PMID: 33158881 Free PMC article.
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.
Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. Griffith DE, et al. Among authors: winthrop k. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416. doi: 10.1164/rccm.200604-571ST. Am J Respir Crit Care Med. 2007. PMID: 17277290 Review. No abstract available.
Infection Risk and Safety of Corticosteroid Use.
Youssef J, Novosad SA, Winthrop KL. Youssef J, et al. Among authors: winthrop kl. Rheum Dis Clin North Am. 2016 Feb;42(1):157-76, ix-x. doi: 10.1016/j.rdc.2015.08.004. Epub 2015 Oct 24. Rheum Dis Clin North Am. 2016. PMID: 26611557 Free PMC article. Review.
Neutralizing monoclonal antibodies for treatment of COVID-19.
Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Taylor PC, et al. Among authors: winthrop k. Nat Rev Immunol. 2021 Jun;21(6):382-393. doi: 10.1038/s41577-021-00542-x. Epub 2021 Apr 19. Nat Rev Immunol. 2021. PMID: 33875867 Free PMC article. Review.
376 results